Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;25(5):205–212. doi: 10.1002/clc.4950250503

Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy

Alan Cheng 1, Joel B Braunstein 1, Cheryl Dennison 1, Caitlin Nass 1, Roger S Blumenthal 1,✉
PMCID: PMC6653857  PMID: 12018878

Abstract

Cardiovascular disease (CVD) is the leading cause of death and disability in industrialized societies, due in large part to the lack of a comprehensive approach to control the risk factors for atherosclerosis. One strategy for reducing an individual's global CVD risk relies on a targeted approach that modifies each of the major independent risk factors prevalent in both symptomatic (secondary prevention) and asymptomatic (primary prevention) patients. These interventions include lipid lowering, smoking cessation, blood pressure control, glycemic control, regular exercise, and the use of various medications. This review offers an evidence‐based strategy toward reducing an individual's global risk for CVD by addressing the modifiable, major independent risk factors.

Keywords: prevention, risk factors, lipids, hypertension, lifestyle

Full Text

The Full Text of this article is available as a PDF (53.1 KB).

References

  • 1. The International Task Force for Prevention of Coronary Heart Disease : Coronary heart disease: Reducing the risk. Nutr Metab Cardiovasc Dis 1998; 8:205–271 [Google Scholar]
  • 2. American Heart Association : 2000. Heart and Stroke Statistical Update. Annual AHA Meeting in Dallas, Texas 1999
  • 3. Kannel WB: The Framingham study: Its 50‐year legacy and future promise. J Ather Thromb 2000; 6:60–66 [DOI] [PubMed] [Google Scholar]
  • 4. Smith SC, Greenland P, Grundy SM: Prevention conference V: Beyond secondary prevention: Identifying the high risk patient for primary prevention. Circulation 2000; 101:111–116 [DOI] [PubMed] [Google Scholar]
  • 5. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houtson‐Miller N, Kris‐Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr: Primary prevention of coronary heart disease: Guidance from Framingham. Circulation 1998; 97:1876–1887 [DOI] [PubMed] [Google Scholar]
  • 6. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S: The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313:1511–1514 [DOI] [PubMed] [Google Scholar]
  • 7. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Smoking cessation and time course of decreased risks of coronary heart disease in middle‐aged women. Arch Intern Med 1994; 154:169–175 [PubMed] [Google Scholar]
  • 8. Hermanson B, Omenn GS, Kronmal RA, Gersh BJ: Beneficial six‐year outcome of smoking cessation in older men and women with coronary heart disease: Results from the CASS registry. N Engl J Med 1988; 319:1365–1369 [DOI] [PubMed] [Google Scholar]
  • 9. Cameron A, Davis K, Rogers W: Recurrence of angina after coronary artery bypass surgery: Predictors and prognosis. J Am Coll Cardiol 1995; 26:895–899 [DOI] [PubMed] [Google Scholar]
  • 10. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM: A comparison of sustained‐release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195–1202 [DOI] [PubMed] [Google Scholar]
  • 11. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained‐release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685–691 [DOI] [PubMed] [Google Scholar]
  • 12. US Department of Health and Human Services : Smoking cessation: Clinical practice guidelines. Research Publication No. 96‐0692, 1996. [Google Scholar]
  • 13. Rigotti NA, McKook KM, Shiffman S: Predictors of smoking cessation after coronary artery bypass graft surgery: Results of a randomized trial with 5‐year follow‐up. Ann Intern Med 1994; 120:287–293 [DOI] [PubMed] [Google Scholar]
  • 14. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D: The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000; 342:1–8 [DOI] [PubMed] [Google Scholar]
  • 15. Malek AM, Alper SL, Izumo S: Hemodynamic shear stress and its role in atherosclerosis. J Am Med Assoc 1999; 282:2035–2042 [DOI] [PubMed] [Google Scholar]
  • 16. O'Donnell CJ, Ridker PM, Glynn RJ, Berger K, Ajani U, Manson JE, Hennekens CH: Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in physicians. Circulation 1997; 95:1132–1137 [DOI] [PubMed] [Google Scholar]
  • 17. Metoprolol Atherosclerosis Prevention in Hypertension Investigators : Primary prevention with metoprolol in patients with hypertension: Mortality results from the MAPHY study. J Am Med Assoc 1988; 259:1976–1982 [PubMed] [Google Scholar]
  • 18. SHEP Cooperative Research Group : Prevention of stroke by anti‐hypertensive drug treatment in older persons with isolated systolic hypertension. J Am Med Assoc 1991; 265:3255–3264 [PubMed] [Google Scholar]
  • 19. JNC VI : The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157:2413–2446 [DOI] [PubMed] [Google Scholar]
  • 20. The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000; 342:145–153 [DOI] [PubMed] [Google Scholar]
  • 21. Grossman E, Messerli FH, Neutel JM: Angiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitors? Arch Intern Med 2000; 160:1905–1911 [DOI] [PubMed] [Google Scholar]
  • 22. The SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327:669–677 [DOI] [PubMed] [Google Scholar]
  • 23. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double‐blind treatment with a long‐acting calcium‐channel blocker or diuretic in the international nifedipine GITS study. Lancet 2000; 356:366–372 [DOI] [PubMed] [Google Scholar]
  • 24. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension. Lancet 1998; 351:1755–1762 [DOI] [PubMed] [Google Scholar]
  • 25. Meade TW, Brennan PJ: Determination of who may derive most benefit from aspirin in primary prevention: Subgroup results from a randomised controlled trial. Br Med J 2000; 321:13–17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double‐blind comparison of placebo and active treatment for older patients with comparison of placebo and avtive treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757–764 [DOI] [PubMed] [Google Scholar]
  • 27. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, de Leeuw PW, Dobovisek J, Jaaskivi M, Leonetti G, O'Brien E, Palatini P, Parati G, Rodicio JL, Vanhanen H, Webster J: Response to antihypertensive therapy in older patients with sustained and non‐sustained systolic hypertension. Circulation 2000; 102:1139–1144 [DOI] [PubMed] [Google Scholar]
  • 28. ALLHAT Collaborative Research Group : Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. J Am Med Assoc 2000; 283:1967–1975 [PubMed] [Google Scholar]
  • 29. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA: Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700–1707 [DOI] [PubMed] [Google Scholar]
  • 30. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nedeljkovic S, Nissinen A, Toshima H: Serum total cholesterol and long‐term coronary heart disease mortality in different cultures. Twenty‐five‐year follow‐up of the seven countries study. J Am Med Assoc 1995; 274:131–136 [PubMed] [Google Scholar]
  • 31. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: High density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989; 79:8–15 [DOI] [PubMed] [Google Scholar]
  • 32. Lipid Research Clinics Coronary Primary Prevention Trial Investigators : Reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251:351–364 [DOI] [PubMed] [Google Scholar]
  • 33. Lipid Research Clinics Coronary Primary Prevention Trial Investigators : The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984; 251:365–374 [PubMed] [Google Scholar]
  • 34. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301–1307 [DOI] [PubMed] [Google Scholar]
  • 35. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998; 279:1615–1622 [DOI] [PubMed] [Google Scholar]
  • 36. National Cholesterol Education Program Expert Panel : Executive summary of the third report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults. J Am Med Assoc 2001; 285:2486–2497 [DOI] [PubMed] [Google Scholar]
  • 37. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations of coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992; 85:37–45 [DOI] [PubMed] [Google Scholar]
  • 38. Pearson TA : Matching intensity of intervention with risk for coronary events: Targets for LDL‐C, HDL‐C and other risk factors. Prev Cardiol 1999; 2(suppl): 11–17 [Google Scholar]
  • 39. American Diabetes Association : Clinical practice recommendations 2000. Diabetes Care 2000; 23:S20–24 [PubMed] [Google Scholar]
  • 40. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229–234 [DOI] [PubMed] [Google Scholar]
  • 41. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long‐term coronary, cardiovascular, and all‐cause mortality and to longevity. J Am Med Assoc 2000; 284:311–318 [DOI] [PubMed] [Google Scholar]
  • 42. Scandinavian Simvastatin Survival Study Group : Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease. Lancet 1994; 344:1383–1389 [PubMed] [Google Scholar]
  • 43. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001–1009 [DOI] [PubMed] [Google Scholar]
  • 44. Long‐Term Intervention with Pravastatin in Ischemic Disease Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349–1357 [DOI] [PubMed] [Google Scholar]
  • 45. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C: Long‐term effects on clinical outcomes of aggressive lowering of low‐density lipoprotein cholesterol levels and low‐dose anticoagulation in the post coronary artery bypass graft trial. Circulation 2000; 102:157–165 [DOI] [PubMed] [Google Scholar]
  • 46. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high‐density lipoprotein cholesterol. N Engl J Med 1999; 341:410–418 [DOI] [PubMed] [Google Scholar]
  • 47. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen and progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998; 280:605–613 [DOI] [PubMed] [Google Scholar]
  • 48. Kannel WB, McGee DL: Diabetes and cardiovascular disease. J Am Med Assoc 1979; 241:2035–2038 [DOI] [PubMed] [Google Scholar]
  • 49. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease. Circulation 1999; 100:1134–1146 [DOI] [PubMed] [Google Scholar]
  • 50. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21:69–75 [DOI] [PubMed] [Google Scholar]
  • 51. Diabetes Control and Complications Trial Research Group : The effects of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329:977–986 [DOI] [PubMed] [Google Scholar]
  • 52. Wilson WF, Cupples AD, Kannel WB: Is hyperglycemia associated with cardiovascular disease? Am Heart J 1991; 2:586–590 [DOI] [PubMed] [Google Scholar]
  • 53. UK Prospective Diabetes Study Group : Tight blood pressure control risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 17:703–713 [PMC free article] [PubMed] [Google Scholar]
  • 54. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: Prospective observational study. Br Med J 2000; 321:405–412 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med 1998; 105(1A): 77S–82S [DOI] [PubMed] [Google Scholar]
  • 56. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic‐based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. J Am Med Assoc 1996; 276:1886–1892 [PubMed] [Google Scholar]
  • 57. Deedwania PC: Hypertension and diabetes. Arch Intern Med 2000; 160:1585–1594 [DOI] [PubMed] [Google Scholar]
  • 58. HOPE Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Lancet 2000; 355:253–259 [PubMed] [Google Scholar]
  • 59. Willett WC, Dietz H, Colditz GA: Guidelines for healthy weight. N Engl J Med 1999; 341:427–434 [DOI] [PubMed] [Google Scholar]
  • 60. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH: Weight, weight change and coronary heart disease in women: Risk within the “normal” weight range. J Am Med Assoc 1995; 273;461–466 [DOI] [PubMed] [Google Scholar]
  • 61. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343:16–22 [DOI] [PubMed] [Google Scholar]
  • 62. US Department of Health and Human Services : NIH clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report. Obesity Res 1998; 6(suppl2): 51S–209S [PubMed] [Google Scholar]
  • 63. Fletcher G: Physical activity as a risk factor for cardiovascular disease. Am J Med 1999; 107(2A): 10S–11S [DOI] [PubMed] [Google Scholar]
  • 64. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA: Cardiac rehabilitation after myocardial infarction: Combined experience of randomized clinical trials. J Am Med Assoc 1988; 260:945–950 [PubMed] [Google Scholar]
  • 65. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS Jr, Hennekens CH: An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80:234–244 [DOI] [PubMed] [Google Scholar]
  • 66. Vanhees L, Fagard R, Thijs L, Amery A: Prognostic value of training‐induced change in peak exercise capacity in patients with myocardial infarcts and patients with coronary bypass surgery. Am J Cardiol 1995; 76:1014–1019 [DOI] [PubMed] [Google Scholar]
  • 67. Fletcher GF: How to implement physical activity in primary and secondary prevention. Circulation 1997; 96:355–357 [DOI] [PubMed] [Google Scholar]
  • 68. Shephard RJ, Balady GJ: Exercise as cardiovascular therapy. Circulation 1999; 99:963–972 [DOI] [PubMed] [Google Scholar]
  • 69. Van Camp SP, Peterson RA: Cardiovascular complications of outpatient cardiac rehabilitation programs. J Am Med Assoc 1986; 256:1160–1163 [DOI] [PubMed] [Google Scholar]
  • 70. Leon AS, Connett J: Physical activity and 10.5 year mortality in the multiple risk factor intervention trial. Int J Epidemiol 1991; 20:690–697 [DOI] [PubMed] [Google Scholar]
  • 71. Hakim AA, Curb JD, Petrovitch H, Rodriguez BL, Yano K, Ross GW, White LR, Abbott RD: Effects of walking on coronary heart disease in elderly men. Circulation 1999; 100:9–13 [DOI] [PubMed] [Google Scholar]
  • 72. Manson JE, Hu FB, Rich‐Edwards JW, Colditz GA, Stampfer MJ, Willett WC, Speizer FE, Hennekens CH: A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999; 341:650–658 [DOI] [PubMed] [Google Scholar]
  • 73. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, Kriska A, Leon AS, Marcus BH, Morris J, Paffenbarger RS, Patrick K, Pollock ML, Rippe JM, Sallis J, Wilmore JH: Physical activity and public health. J Am Med Assoc 1995; 273:402–407 [DOI] [PubMed] [Google Scholar]
  • 74. CAPRIE Steering Group : A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996; 348:1329–1339 [DOI] [PubMed] [Google Scholar]
  • 75. Colwell JA: Aspirin therapy in diabetes. Diabetes Care 1997; 20:1767–1771 [DOI] [PubMed] [Google Scholar]
  • 76. He J, Vupputuri S, Allen K, Prerost MR, Hughes JM, Whelton PK: Passive smoking and the risk of coronary heart disease–a meta‐analysis of epidemiologic studies. N Engl J Med 1999; 340:920–926 [DOI] [PubMed] [Google Scholar]
  • 77. Feiner AS: Homocyst(e)ine and cardiovascular disease (letter). Ann Intern Med 2000; 132:676 [DOI] [PubMed] [Google Scholar]
  • 78. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340:1449–1454 [DOI] [PubMed] [Google Scholar]
  • 79. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP: Elevated plasma lipoprotein(a) and coronary heart disease in men 55 years old and younger: A prospective study. J Am Med Assoc 1996; 276:544–548 [DOI] [PubMed] [Google Scholar]
  • 80. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J Am Med Assoc 1995; 274:1771–1774 [PubMed] [Google Scholar]
  • 81. Ciruzzi M, Schargrodsky H, Rozlosnik J, Pramparo P, Delmonte H, Rudich V, Piskorz D, Negri E, Soifer S, La Vecchia C: Frequency of family history in patients with acute MI. Am J Cardiol 1997; 80:122–127 [DOI] [PubMed] [Google Scholar]
  • 82. Williams R, Bhopal R, Hunt K: Coronary risk in a British Punjabi population: A comparative profile of non‐biochemical factors. Int J Epidemiol 1994; 23:28–37 [DOI] [PubMed] [Google Scholar]
  • 83. Goff DC, Ramsey DJ, Labarthe DR, Nichaman MZ: Greater case‐fatality after myocardial infarction among Mexican Americans and women than among non‐Hispanic whites and men. Am J Epidemiol 1994; 139:474–483 [DOI] [PubMed] [Google Scholar]
  • 84. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, Lonn E, Gerstein H, Hegele RA, McQueen M: Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada. Lancet 2000; 356:279–284 [DOI] [PubMed] [Google Scholar]
  • 85. Kubzandsky LD, Kawachi I, Spiro A, Weiss ST, Vokonas PS, Sparrow D: Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the normative aging study. Circulation 1997; 95:818–824 [DOI] [PubMed] [Google Scholar]
  • 86. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C‐reactive protein, albumin or leukocyte count with coronary heart disease. J Am Med Assoc 1998; 279:1477–1482 [DOI] [PubMed] [Google Scholar]
  • 87. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE: Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation 1997; 96:1102–1108 [DOI] [PubMed] [Google Scholar]
  • 88. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C‐reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle‐aged men. Circulation 1999; 99:237–242 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES